https://supplements.retinatoday.com/articles/not-rated/hello-world/2018-09-10T16:29:09+00:00https://supplements.retinatoday.com/articles/the-blueprint-for-exceptional-image-quality/hak-test/2018-09-12T04:20:00+00:00https://supplements.retinatoday.com/articles/clinical-case-compendium/management-of-subretinal-pvr-bands/2018-10-11T16:26:14+00:00https://supplements.retinatoday.com/articles/clinical-case-compendium/viscodissection-in-the-management-of-a-complex-diabetic-trd/2018-10-11T16:28:02+00:00https://supplements.retinatoday.com/articles/clinical-case-compendium/challenging-diabetic-trd-repair/2018-10-11T16:29:29+00:00https://supplements.retinatoday.com/articles/clinical-case-compendium/management-of-retinal-folds-after-rd/2018-10-08T19:44:32+00:00https://supplements.retinatoday.com/articles/clinical-case-compendium/repair-of-a-trd-in-a-patient-with-proliferative-diabetic-retinopathy/2018-10-22T15:12:22+00:00https://supplements.retinatoday.com/articles/diabetic-retinopathy-changing-treatment-paradigms/diabetic-retinopathy-changing-treatment-paradigms/2020-04-22T14:46:00+00:00https://supplements.retinatoday.com/articles/diabetic-retinopathy-changing-treatment-paradigms/case-1-managing-diabetic-retinopathy-in-working-age-patients/2018-11-08T17:23:50+00:00https://supplements.retinatoday.com/articles/diabetic-retinopathy-changing-treatment-paradigms/case-2-how-and-why-anti-vegf-therapy-fits-into-a-diabetic-retinopathy-treatment-paradigm/2018-11-08T17:23:55+00:00https://supplements.retinatoday.com/articles/diabetic-retinopathy-changing-treatment-paradigms/case-3-learning-from-treatment-failures/2018-11-08T17:24:02+00:00https://supplements.retinatoday.com/articles/diabetic-retinopathy-changing-treatment-paradigms/diabetic-retinopathy-changing-treatment-paradigms-2/2019-01-28T20:55:12+00:00https://supplements.retinatoday.com/articles/diabetic-retinopathy-changing-treatment-paradigms/setting-the-stage/2019-02-20T19:56:46+00:00https://supplements.retinatoday.com/articles/diabetic-retinopathy-changing-treatment-paradigms/the-role-of-imaging/2019-02-20T20:00:36+00:00https://supplements.retinatoday.com/articles/diabetic-retinopathy-changing-treatment-paradigms/threshold-for-treatment/2019-01-23T15:45:41+00:00https://supplements.retinatoday.com/articles/diabetic-retinopathy-changing-treatment-paradigms/clinical-trial-data-and-real-world-practice/2020-02-28T15:28:46+00:00https://supplements.retinatoday.com/articles/diabetic-retinopathy-changing-treatment-paradigms/closing-comments/2019-01-28T20:52:50+00:00https://supplements.retinatoday.com/articles/a-new-vision-in-retinal-gene-therapy-from-clinical-trials-to-clinical-practice/setting-the-scene-developing-a-retinal-gene-therapy-for-rpe65-mutations/2020-05-21T18:30:08+00:00https://supplements.retinatoday.com/articles/a-new-vision-in-retinal-gene-therapy-from-clinical-trials-to-clinical-practice/patient-selection-informing-diagnosis-through-relevant-testing/2020-05-13T17:52:57+00:00https://supplements.retinatoday.com/articles/a-new-vision-in-retinal-gene-therapy-from-clinical-trials-to-clinical-practice/retinal-gene-therapy-in-clinical-practice-perspectives-from-an-expert-center/2020-05-13T17:52:49+00:00https://supplements.retinatoday.com/articles/a-new-vision-in-retinal-gene-therapy-from-clinical-trials-to-clinical-practice/conclusion/2020-05-13T18:16:14+00:00https://supplements.retinatoday.com/articles/ranibizumab-retinal-care-for-all-ages-rival-namd-to-rainbow-rop/changing-clinical-paradigm-in-diabetic-retinopathy/2020-01-30T17:54:04+00:00https://supplements.retinatoday.com/articles/ranibizumab-retinal-care-for-all-ages-rival-namd-to-rainbow-rop/a-new-horizon-in-rop-the-rainbow-study/2020-01-30T17:54:15+00:00https://supplements.retinatoday.com/articles/ranibizumab-retinal-care-for-all-ages-rival-namd-to-rainbow-rop/clinical-perspectives-on-ranibizumab-as-a-therapy-for-all-ages/2020-01-30T17:54:24+00:00https://supplements.retinatoday.com/articles/new-horizons-in-namd-treatment/part-1-challenges-and-opportunities-in-namd-care/2020-12-09T18:30:06+00:00https://supplements.retinatoday.com/articles/new-horizons-in-namd-treatment/part-2-clinical-perspectives-on-current-considerations-in-namd-management/2020-12-09T18:30:13+00:00https://supplements.retinatoday.com/articles/new-horizons-in-namd-treatment/part-3-new-therapy-for-namd-updates-from-an-advanced-clinical-program/2020-12-09T18:30:20+00:00https://supplements.retinatoday.com/articles/new-horizons-in-namd-treatment/part-4-clinical-perspectives-on-evidence-from-recent-and-upcoming-trials-in-namd/2020-12-09T18:30:30+00:00https://supplements.retinatoday.com/articles/new-horizons-in-namd-treatment/summary-and-closing-comments-2/2020-12-09T18:30:38+00:00https://supplements.retinatoday.com/articles/ss-oct-clinical-applications-for-diagnosing-and-following-ocular-pathology/ss-oct-clinical-applications-for-diagnosing-and-following-ocular-pathology/2020-03-11T19:55:36+00:00https://supplements.retinatoday.com/articles/improved-technology-speedier-clinics-and-tailored-treatments/introduction/2020-04-23T16:19:11+00:00https://supplements.retinatoday.com/articles/improved-technology-speedier-clinics-and-tailored-treatments/octas-utility-in-a-number-of-diseases/2020-04-23T16:19:17+00:00https://supplements.retinatoday.com/articles/improved-technology-speedier-clinics-and-tailored-treatments/enhanced-ultrawide-field-imaging-on-the-clarus-700/2020-04-23T16:19:22+00:00https://supplements.retinatoday.com/articles/improved-technology-speedier-clinics-and-tailored-treatments/octa-in-diabetic-retinopathy-and-uveitis/2020-04-23T16:19:29+00:00https://supplements.retinatoday.com/articles/providing-inflammatory-control-in-a-patient-with-relentless-placoid-chorioretinitis/providing-inflammatory-control-in-a-patient-with-relentless-placoid-chorioretinitis/2023-03-15T18:05:52+00:00https://supplements.retinatoday.com/articles/refining-the-use-of-oct-in-diagnosing-glaucoma/refining-the-use-of-oct-in-diagnosing-glaucoma/2020-04-17T17:35:05+00:00https://supplements.retinatoday.com/articles/retinopathy-of-prematurity-transforming-treatment-paradigms/retinopathy-of-prematurity-transforming-treatment-paradigms/2020-09-22T18:04:09+00:00https://supplements.retinatoday.com/articles/retinopathy-of-prematurity-transforming-treatment-paradigms/a-neonatal-perspective-on-preterm-morbidity-and-retinopathy/2020-09-22T18:02:30+00:00https://supplements.retinatoday.com/articles/retinopathy-of-prematurity-transforming-treatment-paradigms/rop-epidemiology-and-clinical-perspective/2020-09-22T18:02:08+00:00https://supplements.retinatoday.com/articles/retinopathy-of-prematurity-transforming-treatment-paradigms/clinical-research-studies-on-anti-vegfs/2020-09-22T18:01:49+00:00https://supplements.retinatoday.com/articles/retinopathy-of-prematurity-transforming-treatment-paradigms/discussion-current-clinical-considerations-on-rop/2020-09-22T18:01:12+00:00https://supplements.retinatoday.com/articles/retinopathy-of-prematurity-transforming-treatment-paradigms/summary-and-closing-comments/2022-02-11T14:27:02+00:00https://supplements.retinatoday.com/articles/unexpected-benefits-with-digital-surgical-viewing-additional-safety-measures-during-covid-19/unexpected-benefits-with-digital-surgical-viewing-additional-safety-measures-during-covid-19/2020-08-19T16:32:59+00:00https://supplements.retinatoday.com/articles/retinopathy-of-prematurity-transforming-treatment-paradigms/introduction-2/2020-09-22T18:02:42+00:00https://supplements.retinatoday.com/articles/treatment-adherence-in-neovascular-amd/treatment-adherence-in-neovascular-amd/2021-06-16T17:04:51+00:00https://supplements.retinatoday.com/articles/treatment-adherence-in-neovascular-amd/case-1-return-of-fluid-results-in-failure-to-extend/2021-06-16T11:57:28+00:00https://supplements.retinatoday.com/articles/treatment-adherence-in-neovascular-amd/case-2-covid-19-and-ltfu-implications-of-missed-anti-vegf-doses/2021-06-02T14:03:21+00:00https://supplements.retinatoday.com/articles/treatment-adherence-in-neovascular-amd/case-3-taking-your-foot-off-the-gas-fallout-from-relaxing-treatment-intensity/2021-06-03T14:55:30+00:00https://supplements.retinatoday.com/articles/treatment-adherence-in-neovascular-amd-2/treatment-adherence-in-neovascular-amd-2/2021-06-16T17:03:59+00:00https://supplements.retinatoday.com/articles/treatment-adherence-in-neovascular-amd-2/case-3-taking-your-foot-off-the-gas-fallout-from-relaxing-treatment-intensity-2/2021-06-16T11:53:31+00:00https://supplements.retinatoday.com/articles/treatment-adherence-in-neovascular-amd-2/case-2-covid-19-and-ltfu-implications-of-missed-anti-vegf-doses-2/2021-06-16T11:53:22+00:00https://supplements.retinatoday.com/articles/treatment-adherence-in-neovascular-amd-2/case-1-return-of-fluid-results-in-failure-to-extend-2/2021-06-16T11:53:10+00:00